Go Pro
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$230.70
+3.4%		$252.22
$186.05
▼
$282.15
$14.82B0.35765,396 shs1.14 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$57.95
+2.2%		$55.58
$33.76
▼
$59.72
$14.41B0.422.08 million shs1.93 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$16.38
-0.4%		$14.86
$12.07
▼
$29.23
$13.66B-1.246.27 million shs5.04 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+80.27%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.39%-3.49%-8.81%-11.52%+19.36%
Exelixis, Inc. stock logo
EXEL
Exelixis
+2.15%-0.92%+2.17%+5.81%+48.93%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-0.43%-7.56%+22.60%+16.92%-20.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$230.70
+3.4%		$252.22
$186.05
▼
$282.15
$14.82B0.35765,396 shs1.14 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$57.95
+2.2%		$55.58
$33.76
▼
$59.72
$14.41B0.422.08 million shs1.93 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$16.38
-0.4%		$14.86
$12.07
▼
$29.23
$13.66B-1.246.27 million shs5.04 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+80.27%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+3.39%-3.49%-8.81%-11.52%+19.36%
Exelixis, Inc. stock logo
EXEL
Exelixis
+2.15%-0.92%+2.17%+5.81%+48.93%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-0.43%-7.56%+22.60%+16.92%-20.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.14
Hold$38.88-5.25% Downside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7534.70% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.29-13.23% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.41
Hold$25.9158.17% Upside

Current Analyst Ratings Breakdown

Latest APLS, ASND, EXEL, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/23/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/22/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/14/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/9/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone logo
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$1.11B4.75$0.21 per share196.33$3.24 per share12.66
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.67N/AN/A($2.97) per share-77.68
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.19$3.02 per share19.21$8.06 per share7.19
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.9026.01N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.2215.581.7335.33%42.17%31.76%11/3/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest APLS, ASND, EXEL, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.87
3.63
3.16
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770128.02 million119.70 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Earns Neutral Rating from HC Wainwright
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046986
Summit Therapeutics (NASDAQ:SMMT) Receives "Neutral" Rating from HC Wainwright
September 23 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-summit-therapeutics-nasdaq-smmt-receives-neutral-rating-from-hc-wainwright-2026-09-23/
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...
September 22 at 8:24 AM  |  marketscreener.comM
Barclays Keeps Their Hold Rating on Summit Therapeutics (SMMT)
September 22 at 8:24 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SMMT/pressreleases/4725481/barclays-keeps-their-hold-rating-on-summit-therapeutics-smmt/
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260922660020/en/HARMONi-GI1-a-Phase-III-Trial-Featuring-Ivonescimab-Plus-Chemotherapy-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Treatment-of-Patients-with-Advanced-Biliary-Tract-Cancer-from-China-to-Be-Showcased-in-Presidential-Symposium-at-ESMO-2026/
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Brokerages
September 22 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31038888
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Analysts
September 22 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-summit-therapeutics-plc-nasdaq-smmt-receives-consensus-rating-of-hold-from-analysts-2026-09-22/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.8% - Should You Sell?
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-down-58-should-you-sell-2026-09-21/
Engineers Gate Manager LP Makes New Investment in Summit Therapeutics PLC $SMMT
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-makes-new-investment-in-summit-therapeutics-plc-smmt-2026-09-20/
Summit Therapeutics: It's Okay Not To Have An Answer
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947471-summit-therapeutics-its-okay-not-to-have-an-answer
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SMMT/pressreleases/4613211/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-and-azenta-azta/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-down-7-should-you-sell-2026-09-15/
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260915307340/en/Updated-HARMONi-Data-Presented-at-WCLC-2026-Demonstrate-Consistent-Overall-Survival-Results-with-Ivonescimab-Plus-Chemotherapy-in-Western-and-Asian-Patients/
Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Ivonescimab+cuts+death+risk+27%25+vs.+pembrolizumab+in+lung+cancer/27054356.html
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Business+Wire/Ivonescimab+Monotherapy+Demonstrates+a+Statistically+Significant+%26amp%3B+Clinically+Meaningful+Benefit+Compared+to+Pembrolizumab+Monotherapy+in+PD-L1-Positive+Advanced+NSCLC+in+Akeso%E2%80%99s+HARMONi-2+Study/27054259.html
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
September 13, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-s-ivonescimab-cuts-death-risk-by-27-versus-keytruda-in-lung-cancer-trial/ar-AA2c8ugF
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
September 13, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9078710/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pdl1positive-advanced-nsclc-in-akesos-harmoni2-study-condu
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
September 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260913549808/en/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pd-l1-positive-advanced-nsclc-in-akeso%e2%80%99s-harmoni-2-study-conducted-in-china/
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-120560-summit-therapeutics-plc-smmt-2026-09-12/
Summit Therapeutics PLC (SMMT)
September 10, 2026  |  fr.investing.comhttps://fr.investing.com/equities/summit-therapeutics-plc-news
Summit Therapeutics Shares Rise After Upgrade From Jefferies
September 9, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$230.70 +7.57 (+3.39%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$242.99 +12.29 (+5.33%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$57.95 +1.22 (+2.15%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$58.00 +0.05 (+0.09%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$16.38 -0.07 (-0.43%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$16.42 +0.04 (+0.24%)
As of 05:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas